Aim of the webinar
In October 2024, a European nuclear reactor, supplier of materials used in the production of Tc99, went down for a second time in just 18 months. The temporary shutdown left surgeons across the world scrambling for a non-inferior alternative to get through their patient lists without delay. But which solutions can truly offer that?
This webinar will address how surgeons need to consider a future without Tc99 as an option for sentinel lymph node biopsy, and the effectiveness and reliability of the potential replacements.
It will assess the long-term availability of radioactive isotopes, review the proven clinical efficacy of tracers, before analysing the logistical benefits, opportunities for further utilisation, advanced techniques, and additional benefits for patients.
Speakers
